These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 17986662)

  • 1. Induction of regulatory T cell-resistant helper CD4+ T cells by bacterial vector.
    Nishikawa H; Tsuji T; Jäger E; Briones G; Ritter G; Old LJ; Galán JE; Shiku H; Gnjatic S
    Blood; 2008 Feb; 111(3):1404-12. PubMed ID: 17986662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients.
    Nishikawa H; Jäger E; Ritter G; Old LJ; Gnjatic S
    Blood; 2005 Aug; 106(3):1008-11. PubMed ID: 15840697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of CD4+CD25+ regulatory T cells on low/high-avidity CD4+ T cells following peptide vaccination.
    Nishikawa H; Qian F; Tsuji T; Ritter G; Old LJ; Gnjatic S; Odunsi K
    J Immunol; 2006 May; 176(10):6340-6. PubMed ID: 16670346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines.
    Nishikawa H; Sato E; Briones G; Chen LM; Matsuo M; Nagata Y; Ritter G; Jäger E; Nomura H; Kondo S; Tawara I; Kato T; Shiku H; Old LJ; Galán JE; Gnjatic S
    J Clin Invest; 2006 Jul; 116(7):1946-54. PubMed ID: 16794737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HLA-DP4 expression and immunity to NY-ESO-1: correlation and characterization of cytotoxic CD4+ CD25- CD8- T cell clones.
    Huarte E; Karbach J; Gnjatic S; Bender A; Jäger D; Arand M; Atanackovic D; Skipper J; Ritter G; Chen YT; Old LJ; Knuth A; Jäger E
    Cancer Immun; 2004 Dec; 4():15. PubMed ID: 15600300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human tumor antigen-specific helper and regulatory T cells share common epitope specificity but exhibit distinct T cell repertoire.
    Fourcade J; Sun Z; Kudela P; Janjic B; Kirkwood JM; El-Hafnawy T; Zarour HM
    J Immunol; 2010 Jun; 184(12):6709-18. PubMed ID: 20483736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MHC class II/ESO tetramer-based generation of in vitro primed anti-tumor T-helper lines for adoptive cell therapy of cancer.
    Poli C; Raffin C; Dojcinovic D; Luescher I; Ayyoub M; Valmori D
    Haematologica; 2013 Feb; 98(2):316-22. PubMed ID: 22875619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NY-ESO-1-specific circulating CD4+ T cells in ovarian cancer patients are prevalently T(H)1 type cells undetectable in the CD25+ FOXP3+ Treg compartment.
    Redjimi N; Duperrier-Amouriaux K; Raimbaud I; Luescher I; Dojcinovic D; Classe JM; Berton-Rigaud D; Frenel JS; Bourbouloux E; Valmori D; Ayyoub M
    PLoS One; 2011; 6(7):e22845. PubMed ID: 21829534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificity.
    Tsuji T; Matsuzaki J; Kelly MP; Ramakrishna V; Vitale L; He LZ; Keler T; Odunsi K; Old LJ; Ritter G; Gnjatic S
    J Immunol; 2011 Jan; 186(2):1218-27. PubMed ID: 21149605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lentivector immunization induces tumor antigen-specific B and T cell responses in vivo.
    Garcia Casado J; Janda J; Wei J; Chapatte L; Colombetti S; Alves P; Ritter G; Ayyoub M; Valmori D; Chen W; Lévy F
    Eur J Immunol; 2008 Jul; 38(7):1867-76. PubMed ID: 18546142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stimulation of the glucocorticoid-induced TNF receptor family-related receptor on CD8 T cells induces protective and high-avidity T cell responses to tumor-specific antigens.
    Côté AL; Zhang P; O'Sullivan JA; Jacobs VL; Clemis CR; Sakaguchi S; Guevara-Patiño JA; Turk MJ
    J Immunol; 2011 Jan; 186(1):275-83. PubMed ID: 21106849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory T cell depletion enhances tumor specific CD8 T-cell responses, elicited by tumor antigen NY-ESO-1b in hepatocellular carcinoma patients, in vitro.
    Zhang HH; Mei MH; Fei R; Liao WJ; Wang XY; Qin LL; Wang JH; Wei L; Chen HS
    Int J Oncol; 2010 Apr; 36(4):841-8. PubMed ID: 20198327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients.
    Kitano S; Tsuji T; Liu C; Hirschhorn-Cymerman D; Kyi C; Mu Z; Allison JP; Gnjatic S; Yuan JD; Wolchok JD
    Cancer Immunol Res; 2013 Oct; 1(4):235-44. PubMed ID: 24396833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells.
    Zarour HM; Maillere B; Brusic V; Coval K; Williams E; Pouvelle-Moratille S; Castelli F; Land S; Bennouna J; Logan T; Kirkwood JM
    Cancer Res; 2002 Jan; 62(1):213-8. PubMed ID: 11782380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma.
    Mandic M; Castelli F; Janjic B; Almunia C; Andrade P; Gillet D; Brusic V; Kirkwood JM; Maillere B; Zarour HM
    J Immunol; 2005 Feb; 174(3):1751-9. PubMed ID: 15661941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overcoming regulatory T-cell suppression by a lyophilized preparation of Streptococcus pyogenes.
    Hirayama M; Nishikawa H; Nagata Y; Tsuji T; Kato T; Kageyama S; Ueda S; Sugiyama D; Hori S; Sakaguchi S; Ritter G; Old LJ; Gnjatic S; Shiku H
    Eur J Immunol; 2013 Apr; 43(4):989-1000. PubMed ID: 23436617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral vaccination with attenuated Salmonella enterica strains encoding T-cell epitopes from tumor antigen NY-ESO-1 induces specific cytotoxic T-lymphocyte responses.
    Meng JZ; Dong YJ; Huang H; Li S; Zhong Y; Liu SL; Wang YD
    Clin Vaccine Immunol; 2010 Jun; 17(6):889-94. PubMed ID: 20375244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51.
    Jäger E; Karbach J; Gnjatic S; Jäger D; Maeurer M; Atmaca A; Arand M; Skipper J; Stockert E; Chen YT; Old LJ; Knuth A
    Cancer Immun; 2002 Sep; 2():12. PubMed ID: 12747757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans.
    Sugiyama D; Nishikawa H; Maeda Y; Nishioka M; Tanemura A; Katayama I; Ezoe S; Kanakura Y; Sato E; Fukumori Y; Karbach J; Jäger E; Sakaguchi S
    Proc Natl Acad Sci U S A; 2013 Oct; 110(44):17945-50. PubMed ID: 24127572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of immune response against NY-ESO-1 by CHP-NY-ESO-1 vaccination and immune regulation in a melanoma patient.
    Tsuji K; Hamada T; Uenaka A; Wada H; Sato E; Isobe M; Asagoe K; Yamasaki O; Shiku H; Ritter G; Murphy R; Hoffman EW; Old LJ; Nakayama E; Iwatsuki K
    Cancer Immunol Immunother; 2008 Oct; 57(10):1429-37. PubMed ID: 18311489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.